🇺🇸 FDA

P0 · Therapeutic area intelligence

Neurology & CNS patent intelligence

Alzheimer's, Parkinson's, epilepsy, and CNS pharmaceutical patent landscape.

Patents
268

Quick answer

268 US pharmaceutical patents in our index match Neurology & CNS title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 7550454

    Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

    ACADIA Pharmaceuticals Inc. · Granted Tue Jun 23 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7534613

    Methods of treating parkinson's disease using viral vectors

    The Regents of the University of California · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7517871

    Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

    ACADIA Pharmaceuticals Inc. · Granted Tue Apr 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7491715

    Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

    ACADIA Pharmaceuticals Inc. · Granted Tue Feb 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7479579

    Triple transgenic mouse model of Alzheimer's disease

    The Regents of the University of California · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7470431

    Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer

    The Regents of the University of Colorado · Granted Tue Dec 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7465715

    Method for treatment of multiple sclerosis

    CAN-FITE BIOPHARMA LTD. · Granted Tue Dec 16 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 11 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7258859

    Method for the treatment of multiple sclerosis

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Aug 21 2007 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 16 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 6936599

    Estriol therapy for multiple sclerosis and other autoimmune diseases

    The Regents of the University of California · Granted Tue Aug 30 2005 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  10. US 6894026

    Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders

    Atossa Healthcare, Inc. · Granted Tue May 17 2005 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  11. US 6762032

    Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response

    BioCrystal, Ltd. · Granted Tue Jul 13 2004 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  12. US 6740638

    Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

    Neurocrine Biosciences, Inc. · Granted Tue May 25 2004 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  13. US 6737059

    Methods of inhibiting inflammatory processes and alleviating symptoms associated with multiple sclerosis

    The Board of Regents of the University of Washington · Granted Tue May 18 2004 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  14. US 6673332

    Assays for inhibitors of neuronal transport of Alzheimer's amyloid precursor protein

    The Regents of the University of California · Granted Tue Jan 06 2004 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  15. US 6656930

    Aralkyl diazabicycloalkane derivatives for CNS disorders

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Dec 02 2003 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  16. US 6489299

    Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

    Neurocrine Biosciences, Inc. · Granted Tue Dec 03 2002 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  17. US 6410747

    Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Jun 25 2002 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  18. US 6379670

    Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein

    Neurocrine Biosciences, Inc. · Granted Tue Apr 30 2002 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  19. US 6369033

    Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

    Neurocrine Biosciences, Inc. · Granted Tue Apr 09 2002 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  20. US 6350479

    Treating depression with alcohol extracts of tobacco

    Regent Court Technologies, LLC · Granted Tue Feb 26 2002 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  21. US 6329499

    Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein

    Neurocrine Biosciences, Inc. · Granted Tue Dec 11 2001 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  22. US 6309634

    Methods of treating Parkinson's disease using recombinant adeno-associated vector (rAAV)

    The Regents of the University of California · Granted Tue Oct 30 2001 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  23. US 6310064

    Aralkyl diazabicycloalkane derivatives for CNS disorders

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Oct 30 2001 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  24. US 6251396

    Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein

    Neurocrine Biosciences, Inc. · Granted Tue Jun 26 2001 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  25. US 6248528

    Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders

    The Regents of the University of California · Granted Tue Jun 19 2001 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  26. US 6166008

    Treatment of schizophrenia with ampakines and neuroleptics

    The Regents of the University of California · Granted Tue Dec 26 2000 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 21 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  27. US 6127598

    NKX-2.2 and NKX-6.1 transgenic mouse models for diabetes, depression, and obesity

    The Regents of the University of California · Granted Tue Oct 03 2000 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  28. US 6087326

    Neurological drug screens

    The Regents of the University of California · Granted Tue Jul 11 2000 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 06 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

How many Neurology & CNS patents are indexed?

268 patents match our Neurology & CNS classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.